Smith Anglin Financial’s AbbVie ABBV Stock Holding History

Smith Anglin Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$644K	Buy	3,468 +36	+1%	+$6.69K	0.06%	106
2025 Q1	$719K	Sell	3,432 -544	-14%	-$106K	0.08%	97
2024 Q4	$707K	Buy	3,976 +199	+5%	+$36.6K	0.07%	96
2024 Q3	$746K	Buy	3,777 +237	+7%	+$44.2K	0.07%	89
2024 Q2	$607K	Buy	3,540 +6	+0.2%	+$994	0.06%	94
2024 Q1	$643K	Buy	3,534 +253	+8%	+$43.6K	0.07%	95
2023 Q4	$508K	Buy	3,281 +56	+2%	+$8.16K	0.06%	102
2023 Q3	$481K	Buy	3,225 +29	+0.9%	+$4.26K	0.06%	96
2023 Q2	$431K	Buy	3,196 +35	+1%	+$5.13K	0.05%	105
2023 Q1	$504K	Buy	3,161 +118	+4%	+$18K	0.08%	93
2022 Q4	$492K	Sell	3,043 -73	-2%	-$11.2K	0.09%	81
2022 Q3	$418K	Buy	3,116 +30	+1%	+$4.3K	0.09%	85
2022 Q2	$473K	Sell	3,086 -212	-6%	-$32.4K	0.14%	75
2022 Q1	$535K	Sell	3,298 -6	-0.2%	-$872	0.12%	71
2021 Q4	$447K	Buy	3,304 +218	+7%	+$25.8K	0.08%	90
2021 Q3	$333K	Sell	3,086 -253	-8%	-$28.9K	0.06%	105
2021 Q2	$376K	Buy	3,339 +43	+1%	+$4.84K	0.07%	97
2021 Q1	$357K	Sell	3,296 -44	-1%	-$4.71K	0.08%	96
2020 Q4	$358K	Buy	+3,340	New	+$321K	0.06%	88

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Smith Anglin Financial's ABBV Position: Q2 2025 in Review

Smith Anglin Financial increased its AbbVie (ABBV) stake by 1% in Q2 2025, buying an estimated $6.69K and bringing the position to 3,468 shares worth $644K. The position accounts for 0.06% of the portfolio, ranked #106.

Smith Anglin Financial first reported a position in ABBV in Q4 2020 and has held it in 19 quarters since. The position peaked at $746K in Q3 2024. 3,787 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Smith Anglin Financial held 3,468 shares of AbbVie worth $644K as of Q2 2025.
Smith Anglin Financial bought 36 AbbVie shares in Q2 2025, an estimated $6.69K.
AbbVie made up 0.06% of Smith Anglin Financial's portfolio in Q2 2025, its #106 holding.
Smith Anglin Financial first reported a position in AbbVie in Q4 2020 and has held it in 19 quarters since.
Smith Anglin Financial's AbbVie position peaked at $746K in Q3 2024.
3,787 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Smith Anglin Financial's 13F filing for Q2 2025, filed 17 Jul 2025.